| Date | Action | Shares | Price | Value | Owned After |
|---|---|---|---|---|---|
| Mar 11, 2013 | Sell(S) | 300 | $5.79 | $2K | 5.1M |
| Mar 11, 2013 | Sell(S) | 3K | $5.75 | $17K | 5.1M |
| Mar 11, 2013 | Sell(S) | 10K | $5.72 | $57K | 5.0M |
| Mar 11, 2013 | Sell(S) | 5K | $5.71 | $29K | 5.0M |
| Mar 8, 2013 | Sell(S) | 2K | $5.95 | $11K | 5.1M |
| Mar 8, 2013 | Sell(S) | 3K | $5.91 | $15K | 5.1M |
| Mar 8, 2013 | Sell(S) | 3K | $5.92 | $15K | 5.1M |
| Mar 8, 2013 | Sell(S) | 10K | $5.82 | $58K | 5.1M |
Parsed from a single SEC EDGAR Form 4 filing (accession 0001144204-13-014648) within minutes of acceptance. Every field above traces to the original document. Verify it directly:
Connected pages for Protalix BioTherapeutics, Inc.
The public view is the crawlable proof. The same sourced dataset is available through REST and MCP for agents, research scripts, and back-office tools.